What is Bilcare Ltd (BI) share price return in the past 10 years?

Bilcare Ltd share price has appreciated 3.5% annually (CAGR) over the past ten years.

What is the share price of Bilcare Ltd (BI)?

Company share prices are keep on changing according to the market conditions. The current trading price of Bilcare Ltd (BI) on 12-Jun-2026 16:59:59 at 16:59 is 60.00.

What is the P/E ratio of Bilcare?

The latest standalone P/E ratio of Bilcare as of 12-Jun-2026 is 142.70.

What is the P/B ratio of Bilcare Ltd (BI)?

The latest standalone P/B ratio of Bilcare Ltd (BI) as of 12-Jun-2026 is 0.34.

What is the 52-week high and low of Bilcare Ltd (BI)?

The 52-week high of Bilcare Ltd (BI) is Rs. 116.00 and the 52-week low is Rs. 50.00.

Bilcare Ltd (BI) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Bilcare Ltd (BI)
Brand: Bilcare

Bilcare Ltd (BI)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526853 NSE: BI Professional Services | Small Cap | Bilcare Share Price

Bilcare Ltd (BI)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 526853 NSE: BI Professional Services | Small Cap | Bilcare Share Price

Key Metrics

Valuation Multiples

Market Cap

₹141 Cr.

Current Price

₹60

52-Week Low / High

₹50 / 116

TTM EPS

₹0.4

TTM Sales

₹6.9 Cr.

Book Value per Share

₹178.8

P/E Ratio

142.70

Higher than its 5-year historical median

Industry PE

38.3

Price to Book (P/B)

0.34

Lower than its 5-year historical median

Price to Sales (P/S)

20.62

Higher than its 5-year historical median

EV/EBITDA

21.42

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

0.96%

Underperforms industry median

Return on Capital Employed (ROCE)

2.18%

Underperforms industry median

Return on Assets (ROA)

0.87%

Operating Profit Margin

-37.5%

Net Profit Margin

26.44%

Gross Profit Margin

55.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

-14.09%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

-25.09%

Asset Quality

Promoter Holding

30.01%

Pledged shares (%) of Promoter's holding (%)

1.39%

Reserves

₹397 Cr.

Equity

₹23.6 Cr.

Face Value

₹10

All Time Low / High

₹5.00 / 1830.00

Bilcare stock performance

Key Ratios

Check Before You Invest

Quality

Somewhat Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Weak

Check Price chart

Q.1 Is Bilcare Ltd a good quality company?

Bilcare Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Bilcare Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Bilcare Ltd vs industry peers?

Bilcare Ltd revenue CAGR is -41.01%, compared to the industry median CAGR of 0.00%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Bilcare Ltd?

Promoters hold 30.01% of the Bilcare Ltd, with 1.39% of their stake pledged, indicating low pledge risk.

Q.1 Stock return of Bilcare Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 4.7% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	-11.2%	-0.6%	-3.2%	-20.5%	-6.4%	7.6%	6.1%	87.5%	1.9%	2.2%	-
Value Creation Index ⓘ	-1.8	-1.0	-1.2	-2.5	-1.5	-0.5	-0.6	5.3	-0.9	-0.8	-
Growth Parameters ⓘ
Sales ⓘ	315	286	258	240	212	304	430	14	17.6	15.1	7
Sales YoY Gr.	-	-9.5%	-9.8%	-6.9%	-11.7%	43.6%	41.3%	-96.8%	25.9%	-14.1%	-
Adj EPS ⓘ	-29.7	-49	-106.7	-133.3	-50	-9.8	-19.5	14.5	-2.6	0.9	0.4
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	-118%	NA	-
BVPS (₹) ⓘ	264.4	236.3	202.4	68.6	25.1	25.8	18.4	174.3	176.5	178.2	178.8
Adj Net Profit ⓘ	-69.8	-115	-251	-314	-118	-23.1	-45.8	34.2	-6.1	2.2	1
Cash Flow from Ops. ⓘ	28.4	37.3	7.2	62.1	71.1	-0.4	46.3	397	32.8	2.4	-
Debt/CF from Ops. ⓘ	34.3	24.1	119.4	14	10	-1642.7	14.9	0	0.3	4.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-28.7%	-41%	-67.2%	-14.1%
Adj EPS ⓘ	NA	NA	NA	NA
BVPSⓘ	-4.3%	48%	113%	1%
Share Price	3.5%	-2.2%	3.5%	-24.2%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-10.8	-19.6	-48.6	-98.4	-106.7	-38.6	-88	15.1	-1.5	0.5	0.2
Op. Profit Mgn % ⓘ	8.6	-1	0.4	0.8	-2.6	8.3	8.6	-37.2	-51.3	-37.5	-182.3
Net Profit Mgn % ⓘ	-22.1	-40.4	-97.5	-130.9	-55.6	-7.6	-10.7	244.8	-34.9	14.5	14.4
Debt to Equity ⓘ	1.6	1.6	1.8	5.4	12	11.2	15.9	0	0	0	0
Working Cap Days ⓘ	448	278	290	300	346	273	229	5,522	1,826	837	2,316
Cash Conv. Cycle ⓘ	140	61	64	53	36	40	52	1,079	93	62	1,730

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	315	286	258	240	212	304	430	14	18	15
Operating Expenses ⓘ +	300	288	258	240	219	279	393	21	27	21
Manufacturing Costs	13	21	21	22	21	30	36	1	3	1
Material Costs	222	212	183	169	143	190	288	5	10	5
Employee Cost	27	29	29	29	27	32	34	6	6	5
Other Costs ⓘ	39	27	25	20	28	27	35	9	8	10
Operating Profit ⓘ	15	-3	-0	-0	-8	25	37	-7	-9	-6
Operating Profit Margin (%)	4.8%	-1.0%	-0.1%	-0.0%	-3.6%	8.3%	8.5%	-51.1%	-51.8%	-37.5%
Other Income ⓘ +	11	5	14	7	14	14	16	4	9	18
Exceptional Items ⓘ	-117	68	246	0	24	52	27	511	11	0
Interest ⓘ	32	48	56	72	69	75	68	0	2	4
Depreciation ⓘ	101	79	304	248	88	35	35	5	2	3
Profit Before Tax ⓘ	-223	-56	-101	-314	-127	-18	-24	503	6	5
Tax ⓘ	-145	10	-21	1	-24	-19	-6	112	0	1
Profit After Tax	-78	-66	-80	-315	-102	2	-18	391	5	4
PAT Margin (%)	-24.8%	-23.1%	-31.0%	-131.0%	-48.3%	0.6%	-4.1%	2,794.6%	30.3%	26.4%
Adjusted EPS (₹)	-33.2	-28.0	-34.0	-133.0	-43.5	0.8	-7.6	166.0	2.3	1.7
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Bilcare - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	623	556	477	161	59	61	43	410	416	420
Share Capital ⓘ	24	24	24	24	24	24	24	24	24	24
Reserves ⓘ	599	533	453	138	36	37	20	387	392	396
Debt +	976	898	857	868	709	678	690	8	9	10
Long Term Debt	773	714	702	714	559	530	537	8	9	10
Short Term Debt	203	184	155	153	150	149	153	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	47	50	57	72	51	61	79	6	2	2
Others Liabilities ⓘ	342	426	165	213	69	24	3	36	34	22
Total Liabilities ⓘ	1,988	1,931	1,555	1,314	887	823	816	460	461	453
Fixed Assets
Net Fixed Assets ⓘ +	1,177	1,147	844	594	506	473	446	16	63	61
Gross Block	1,568	1,587	1,587	1,585	1,586	901	909	31	78	76
Accumulated Depreciation	392	440	743	991	1,079	429	463	15	14	16
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	553	553	514	513	173	89	81	294	294	294
Inventories	52	30	25	32	22	44	56	1	1	0
Trade Receivables	60	49	41	37	39	72	93	9	5	3
Cash Equivalents	11	6	3	7	5	8	5	12	2	3
Others Assets ⓘ	135	146	128	131	141	136	136	128	97	92
Total Assets ⓘ	1,988	1,931	1,555	1,314	887	823	816	460	461	453

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	28	37	7	62	71	-0	46	397	33	2
PBT ⓘ	-223	-124	-346	-314	-151	-70	-51	-8	-5	5
Adjustment ⓘ	252	128	286	321	352	136	93	390	11	7
Changes in Working Capital ⓘ	-0	35	69	56	-130	-68	5	17	26	-11
Tax Paid ⓘ	-0	-1	-1	-1	-1	1	-1	-1	1	1
Cash Flow From Investing Activity ⓘ +	9	-48	78	2	11	85	6	181	-42	3
Capex	-0	-50	-1	1	-0	1	-1	394	-43	3
Net Investments	8	0	1	1	11	84	7	-213	-0	0
Others ⓘ	1	1	78	0	0	0	0	0	1	0
Cash Flow From Financing Activity ⓘ +	-35	6	-87	-60	-83	-82	-55	-571	-1	-4
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	2	0
Interest Paid ⓘ	0	-48	-56	-72	-69	-75	-68	-0	-2	-4
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-35	54	-31	12	-14	-8	13	-570	-0	-0
Net Cash Flow ⓘ	2	-5	-1	3	-1	2	-4	7	-10	1

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	-12.13	-11.18	-15.48	-98.82	-92.77	2.98	-34.16	172.22	1.29	0.96
ROCE (%)	-11.22	-0.56	-3.23	-20.49	-6.4	7.58	6.06	87.45	1.94	2.18
Asset Turnover Ratio	0.15	0.16	0.15	0.17	0.19	0.36	0.52	0.02	0.04	0.03
PAT to CFO Conversion(x)	N/A	N/A	N/A	N/A	N/A	-0	N/A	1.02	6.6	0.5
Working Capital Days
Receivable Days	71.60	63.90	62	59.30	65.60	66.80	70	1,332.20	148.60	100.20
Inventory Days	104.60	48.10	38.20	43.50	46.40	40	42.70	744.60	13.80	10.80
Payable Days	60.40	83.70	107	139.60	156.10	106.70	88.40	3,116.20	154.50	163.60

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

1.39

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bilcare Ltd FAQs

The current trading price of Bilcare on 12-Jun-2026 16:59 is ₹60.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 11-Jun-2026 the market cap of Bilcare stood at ₹141.3 Cr

The latest P/E ratio of Bilcare as of 11-Jun-2026 is 142.7.

The latest P/B ratio of Bilcare as of 11-Jun-2026 is 0.34.

The 52-week high of Bilcare is ₹116.0 and the 52-week low is ₹50.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bilcare is ₹6.85 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Bilcare Ltd is a average quality company.

The key valuation ratios of Bilcare Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bilcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Bilcare Ltd

Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.

Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.

Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.

Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.

It has representative offices located in Argentina, Bangladesh, Chile, Colombia, Czech Republic, Egypt, France, Indonesia, Iran, Israel, Italy, Jordan, South Korea, Malaysia, Mexico, Pakistan, Saudi Arabia, South Africa, Spain, Taiwan, Thailand, Turkey, Venezuela and Vietnam.

It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddyâ€™s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.

For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.

Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.

In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.

Bilcare Ltd (BI)

Bilcare Ltd (BI)

Bilcare stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bilcare - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bilcare Ltd FAQs

About Bilcare Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Bilcare Ltd (BI)

Bilcare Ltd (BI)

Bilcare stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Bilcare - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Bilcare Ltd FAQs

What is the share price of Bilcare?

What is the market cap of Bilcare?

What is the P/E ratio of Bilcare?

What is the P/B ratio of Bilcare?

What is the 52-week high and low of Bilcare?

What is the TTM revenue of Bilcare?

Is Bilcare Ltd a good quality company?

Is Bilcare Ltd undervalued or overvalued?

Is Bilcare Ltd a good buy now?

About Bilcare Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.